Imugene Ltd (ASX:IMU, OTC:IUGNF) managing director and CEO Leslie Chong and strategic advisor Dr Yuman Fong sit down with Proactive’s Jonathan Jackson to discuss Professor Fong’s expertise and the latest company developments.
Dr Fong is a world-renowned cancer researcher, physician and surgeon whose clinical work has focused on OV for more than 30 years. He is the inventor of OV CF33.
Imugene has dosed the first patient in its trial for bile tract cancer (cholangiocarcinoma) patients. The MAST (metastatic advanced solid tumours) Phase 1 trial has been expanded due to early responses in gastrointestinal cancers, particularly cholangiocarcinoma, using Imugene’s cancer-killing virus CF33, known as VAXINIA. The trial, held at St Vincent’s Hospital, Melbourne, Australia, expects to enrol 10 patients.
Bile tract cancer is a rare and challenging disease, often responding poorly to immunotherapy. A recent study reported a complete response in a patient after receiving a mid-dose of IT-administered VAXINIA monotherapy, with no safety signals observed. The Phase 1 MAST trial has progressed through monotherapy dose escalation cohorts and includes a combination study with pembrolizumab. The CF33 virus, developed by City of Hope, has shown preclinical effectiveness in shrinking various cancer tumours.
Негізгі бет Imugene begins VAXINIA trial for bile tract cancer
Пікірлер: 5